Astellas Wins FDA Approval of Eye Disease Drug Izervay and May Have Edge in Market Battle with Apellis

The FDA has signed off on Iveric’s geographic atrophy treatment Izervay. The nod comes less than three weeks after Astellas’ lone rival in the indication, Apellis’ newly approved Syfovre, was flagged for severe side effects.